Lorcainid

• CAT Number: I031000
• CAS Number: 59729-31-6
• Molecular Formula: C22H27ClN2O
• Molecular Weight: 370.92
• Purity: 98%
• Synonyms: Lorcainid; Lorcainide; Lorcainidum
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: N-(4-chlorophenyl)-2-phenyl-N-(1-propan-2-ylpiperidin-4-yl)acetamide
• InChI: InChI=1S/C22H27ClN2O/c1-17(2)24-14-12-21(13-15-24)25(20-10-8-19(23)9-11-20)22(26)16-18-6-4-3-5-7-18/h3-11,17,21H,12-16H2,1-2H3
• InChIKey: XHOJAWVAWFHGHL-UHFFFAOYSA-N
• SMILES: CC(C)N1CCC(CC1)N(C2=CC=C(C=C2)Cl)C(=O)CC3=CC=CC=C3

Lorcainid（Cat No.:I031000）is a class 1b antiarrhythmic agent used to treat certain types of irregular heartbeats, such as ventricular arrhythmias. It works by blocking sodium channels, which helps to stabilize the electrical activity of the heart, preventing abnormal heart rhythms. Lorcainid has been studied for its effectiveness in managing arrhythmias, particularly in patients with heart conditions like ventricular tachycardia. It is typically administered in a controlled, clinical setting due to potential side effects, including dizziness and changes in heart rate. Ongoing research continues to assess its safety and clinical benefits.

Reference

1: Hampton J. Therapeutic fashion and publication bias: the case of anti-arrhythmic drugs in heart attack. J R Soc Med. 2015 Oct;108(10):418-20. doi: 10.1177/0141076815608562. PubMed PMID: 26459066.
2: Gstöttner M, Ng CK, Gmeiner R. [Lorcainid–electrophysiologic examinations of a new anti-arrhythmia agent]. Acta Med Austriaca. 1978;5(4-5):137-8. German. PubMed PMID: 756123.
3: Del Tredici AL, Ma JN, Piu F, Burstein ES. Identification of the antiarrhythmic drugs amiodarone and lorcainide as potent H3 histamine receptor inverse agonists. J Pharmacol Exp Ther. 2014 Jan;348(1):116-24. doi: 10.1124/jpet.113.208892. Epub 2013 Nov 7. PubMed PMID: 24204014.
4: Chalmers I. The true lorcainide story. BMJ. 2015 Jan 28;350:h287. doi: 10.1136/bmj.h287. PubMed PMID: 25630497.
5: Kersting F, Kasper W, Meinertz T, Just H, Jähnchen E. [Cardiovascular effects of lorcainid, a new anti-arrhythmic substance]. Verh Dtsch Ges Inn Med. 1978;(84):687-9. German. PubMed PMID: 154243.
6: Pond SM, Tozer TN. First-pass elimination. Basic concepts and clinical consequences. Clin Pharmacokinet. 1984 Jan-Feb;9(1):1-25. Review. PubMed PMID: 6362950.
7: Evers J, Büttner-Belz U. Fatal lorcainide poisoning. J Toxicol Clin Toxicol. 1995;33(2):157-9. PubMed PMID: 7897755.
8: Ronfeld RA. Comparative pharmacokinetics of new antiarrhythmic drugs. Am Heart J. 1980 Dec;100(6 Pt 2):978-83. Review. PubMed PMID: 6778195.
9: Hellestrand KJ. Comparison of the efficacy of newly developed antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias. Eur Heart J. 1984 Sep;5 Suppl B:87-94. Review. PubMed PMID: 6437822.
10: Orning OM. The use of tocainide, encainide, lorcainide and flecainide for supraventricular arrhythmias. Eur Heart J. 1984 Sep;5 Suppl B:81-6. PubMed PMID: 6437821.
11: Cowley AJ, Skene A, Stainer K, Hampton JR. The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias. Int J Cardiol. 1993 Jul 1;40(2):161-6. PubMed PMID: 8349379.
12: Witek A, Przyborowski L. Chromatographic (TLC) analysis of diltiazem in pharmaceutical form in presence of other antiarrhythmics. Acta Pol Pharm. 1996 Jan-Feb;53(1):9-12. PubMed PMID: 8960279.
13: Kelliher GJ, Kowey P, Engel T, Wetstein L. Clinical pharmacology of antiarrhythmic agents. Cardiovasc Clin. 1985;16(1):287-305. Review. PubMed PMID: 2874883.
14: Meinertz T, Kasper W, Stengel E, Waldecker B, Löllgen H, Jähnchen E, Bechtold H, Just J. Comparison of the antiarrhythmic activity of mexiletine and lorcainide on ventricular arrhythmias. Z Kardiol. 1982 Jan;71(1):35-8. PubMed PMID: 7039160.
15: Falk RH, O’Brien JL. Lorcainide. A comparative trial with quinidine gluconate in patients with previously untreated ventricular arrhythmias. Chest. 1984 Oct;86(4):537-40. PubMed PMID: 6383741.
16: Meuldermans W, Hurkmans R, Swysen E, Hendrickx J, Thijssen J, Lauwers W, Heykants J. Excretion and metabolism of lorcainide in rats, dogs and man. Eur J Drug Metab Pharmacokinet. 1983 Oct-Dec;8(4):335-49. PubMed PMID: 6673971.
17: Amery WK, Heykants J, Bruyneel K, Terryn R. Bioavailability and saturation of the presystemic metabolism of oral lorcainide therapy initiated in three different dose regimens. Eur J Clin Pharmacol. 1983;24(4):517-9. PubMed PMID: 6861866.
18: McDevitt DG. The clinical pharmacology of lidocaine congeners–review of encainide, flecainide, lorcainide and tocainide. Eur Heart J. 1984 Sep;5 Suppl B:63-6. PubMed PMID: 6437818.
19: Podrid PJ. Antiarrhythmic drug therapy (Part 2). Benefits and hazards. Chest. 1985 Oct;88(4):618-24. Review. PubMed PMID: 3930162.
20: Gillis AM, Kates RE. Clinical pharmacokinetics of the newer antiarrhythmic agents. Clin Pharmacokinet. 1984 Sep-Oct;9(5):375-403. Review. PubMed PMID: 6437721.